Login to Your Account

Swiss Kareus Therapeutics Aims Its KU-046 at Alzheimer's

By Cormac Sheridan
Staff Writer

Monday, January 7, 2013
Undeterred by the recent string of high-profile failures in the field, Kareus Therapeutics SA moved its first-in-class drug candidate for Alzheimer's disease, KU-046, into a Phase I trial in healthy volunteers.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription